

Kevin Marsh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1618125/publications.pdf>

Version: 2024-02-01

120
papers

16,137
citations

28274

55
h-index

20961

115
g-index

125
all docs

125
docs citations

125
times ranked

11133
citing authors

#	ARTICLE	IF	CITATIONS
1	The pathogenic basis of malaria. <i>Nature</i> , 2002, 415, 673-679.	27.8	1,423
2	Indicators of Life-Threatening Malaria in African Children. <i>New England Journal of Medicine</i> , 1995, 332, 1399-1404.	27.0	942
3	Immunity to malaria: more questions than answers. <i>Nature Immunology</i> , 2008, 9, 725-732.	14.5	724
4	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. <i>New England Journal of Medicine</i> , 2012, 367, 2284-2295.	27.0	653
5	Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. <i>Nature Medicine</i> , 1998, 4, 358-360.	30.7	578
6	Malaria: Biology and Disease. <i>Cell</i> , 2016, 167, 610-624.	28.9	576
7	Relation between severe malaria morbidity in children and level of <i>Plasmodium falciparum</i> transmission in Africa. <i>Lancet, The</i> , 1997, 349, 1650-1654.	13.7	561
8	Analysis of <i>Plasmodium falciparum</i> diversity in natural infections by deep sequencing. <i>Nature</i> , 2012, 487, 375-379.	27.8	450
9	Immunity to non-cerebral severe malaria is acquired after one or two infections. <i>Nature Medicine</i> , 1999, 5, 340-343.	30.7	433
10	Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. <i>Lancet, The</i> , 2008, 372, 1555-1562.	13.7	386
11	Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age. <i>New England Journal of Medicine</i> , 2008, 359, 2521-2532.	27.0	365
12	Genome-wide and fine-resolution association analysis of malaria in West Africa. <i>Nature Genetics</i> , 2009, 41, 657-665.	21.4	345
13	Breadth and Magnitude of Antibody Responses to Multiple <i>Plasmodium falciparum</i> Merozoite Antigens Are Associated with Protection from Clinical Malaria. <i>Infection and Immunity</i> , 2008, 76, 2240-2248.	2.2	342
14	Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. <i>New England Journal of Medicine</i> , 2016, 374, 2519-2529.	27.0	336
15	Antigens induced on erythrocytes by <i>P. falciparum</i> : expression of diverse and conserved determinants. <i>Science</i> , 1986, 231, 150-153.	12.6	335
16	Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine. <i>New England Journal of Medicine</i> , 2015, 373, 2025-2037.	27.0	332
17	Immune effector mechanisms in malaria. <i>Parasite Immunology</i> , 2006, 28, 51-60.	1.5	329
18	<i>Plasmodium falciparum</i> rosetting is associated with malaria severity in Kenya. <i>Infection and Immunity</i> , 1995, 63, 2323-2326.	2.2	302

#	ARTICLE	IF	CITATIONS
19	Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). <i>International Journal of Epidemiology</i> , 2012, 41, 650-657.	1.9	295
20	Sickle Cell Trait and the Risk of <i>Plasmodium falciparum</i> Malaria and Other Childhood Diseases. <i>Journal of Infectious Diseases</i> , 2005, 192, 178-186.	4.0	285
21	Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1450-1458.	9.1	262
22	Relation between <i>falciparum</i> malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. <i>Lancet</i> , The, 2011, 378, 1316-1323.	13.7	255
23	Human Antibodies Fix Complement to Inhibit <i>Plasmodium falciparum</i> Invasion of Erythrocytes and Are Associated with Protection against Malaria. <i>Immunity</i> , 2015, 42, 580-590.	14.3	250
24	Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure. <i>New England Journal of Medicine</i> , 2013, 368, 1111-1120.	27.0	240
25	Stable and Unstable Malaria Hotspots in Longitudinal Cohort Studies in Kenya. <i>PLoS Medicine</i> , 2010, 7, e1000304.	8.4	221
26	Opsonic phagocytosis of <i>Plasmodium falciparum</i> merozoites: mechanism in human immunity and a correlate of protection against malaria. <i>BMC Medicine</i> , 2014, 12, 108.	5.5	206
27	Case Definitions of Clinical Malaria under Different Transmission Conditions in Kilifi District, Kenya. <i>Journal of Infectious Diseases</i> , 2005, 191, 1932-1939.	4.0	196
28	Targets of antibodies against <i>Plasmodium falciparum</i> -infected erythrocytes in malaria immunity. <i>Journal of Clinical Investigation</i> , 2012, 122, 3227-3238.	8.2	187
29	Human antibodies to recombinant protein constructs of <i>Plasmodium falciparum</i> Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. <i>Vaccine</i> , 2004, 23, 718-728.	3.8	174
30	Examining the human infectious reservoir for <i>Plasmodium falciparum</i> malaria in areas of differing transmission intensity. <i>Nature Communications</i> , 2017, 8, 1133.	12.8	174
31	An Immune Basis for Malaria Protection by the Sickle Cell Trait. <i>PLoS Medicine</i> , 2005, 2, e128.	8.4	169
32	<i>Plasmodium falciparum</i> Variant Surface Antigen Expression Patterns during Malaria. <i>PLoS Pathogens</i> , 2005, 1, e26.	4.7	158
33	New antigens for a multicomponent blood-stage malaria vaccine. <i>Science Translational Medicine</i> , 2014, 6, 247ra102.	12.4	157
34	Transient cross-reactive immune responses can orchestrate antigenic variation in malaria. <i>Nature</i> , 2004, 429, 555-558.	27.8	150
35	Periodicity and space-time clustering of severe childhood malaria on the coast of Kenya. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1993, 87, 386-390.	1.8	135
36	Resistance to malaria through structural variation of red blood cell invasion receptors. <i>Science</i> , 2017, 356, .	12.6	135

#	ARTICLE	IF	CITATIONS
37	<i>Plasmodium falciparum</i> var <i>CI</i> gene expression is modified by host immunity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21801-21806.	7.1	130
38	Naturally acquired immunity to <i>Plasmodium falciparum</i> . Trends in Immunology, 1991, 12, A68-A71.	7.5	126
39	A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. PLOS Clinical Trials, 2006, 1, e29.	3.5	124
40	Host-parasite interaction and morbidity in malaria endemic areas. Philosophical Transactions of the Royal Society B: Biological Sciences, 1997, 352, 1385-1394.	4.0	120
41	A micro-epidemiological analysis of febrile malaria in Coastal Kenya showing hotspots within hotspots. ELife, 2014, 3, e02130.	6.0	115
42	Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Lancet, The, 2019, 393, 2146-2154.	13.7	111
43	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	97
44	The pathogenesis of severe malaria in African children. Annals of Tropical Medicine and Parasitology, 1996, 90, 395-402.	1.6	93
45	IgM in human immunity to <i>Plasmodium falciparum</i> malaria. Science Advances, 2019, 5, eaax4489.	10.3	92
46	Oxidative stress and erythrocyte damage in Kenyan children with severe <i>Plasmodium falciparum</i> malaria. British Journal of Haematology, 2001, 113, 486-491.	2.5	91
47	<i>Plasmodium falciparum</i> antigenic variation. Mapping mosaic <i>var</i> gene sequences onto a network of shared, highly polymorphic sequence blocks. Molecular Microbiology, 2008, 68, 1519-1534.	2.5	91
48	Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study. Lancet Haematology, the, 2018, 5, e333-e345.	4.6	90
49	The Induction and Persistence of T Cell IFN- γ Responses after Vaccination or Natural Exposure Is Suppressed by <i>Plasmodium falciparum</i> . Journal of Immunology, 2007, 179, 4193-4201.	0.8	88
50	Hepatitis B virus infection as a neglected tropical disease. PLoS Neglected Tropical Diseases, 2017, 11, e0005842.	3.0	79
51	Relationship Between Exposure, Clinical Malaria, and Age in an Area of Changing Transmission Intensity. American Journal of Tropical Medicine and Hygiene, 2008, 79, 185-191.	1.4	76
52	Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in <i>Plasmodium falciparum</i> in Kenya. Scientific Reports, 2013, 3, 3318.	3.3	75
53	A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria. Vaccine, 2013, 31, 3936-3942.	3.8	71
54	Age, Spatial, and Temporal Variations in Hospital Admissions with Malaria in Kilifi County, Kenya: A 25-Year Longitudinal Observational Study. PLoS Medicine, 2016, 13, e1002047.	8.4	68

#	ARTICLE	IF	CITATIONS
55	Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 185-91.	1.4	64
56	Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children. <i>Journal of Infectious Diseases</i> , 2011, 204, 9-18.	4.0	60
57	Protection against Clinical Malaria by Heterologous Immunoglobulin G Antibodies against Malaria-Infected Erythrocyte Variant Surface Antigens Requires Interaction with Asymptomatic Infections. <i>Journal of Infectious Diseases</i> , 2004, 190, 1527-1533.	4.0	58
58	An approach to classifying sequence tags sampled from <i>Plasmodium falciparum</i> var genes. <i>Molecular and Biochemical Parasitology</i> , 2007, 154, 98-102.	1.1	55
59	Naturally acquired antibodies to polymorphic and conserved epitopes of <i>Plasmodium falciparum</i> merozoite surface protein 3. <i>Parasite Immunology</i> , 2007, 29, 387-394.	1.5	52
60	An open dataset of <i>Plasmodium falciparum</i> genome variation in 7,000 worldwide samples. <i>Wellcome Open Research</i> , 2021, 6, 42.	1.8	51
61	Limited antigenic diversity of <i>Plasmodium falciparum</i> apical membrane antigen 1 supports the development of effective multi-allele vaccines. <i>BMC Medicine</i> , 2014, 12, 183.	5.5	47
62	Targets and Mechanisms Associated with Protection from Severe <i>Plasmodium falciparum</i> Malaria in Kenyan Children. <i>Infection and Immunity</i> , 2016, 84, 950-963.	2.2	45
63	PfEMP1, polymorphism and pathogenesis. <i>Annals of Tropical Medicine and Parasitology</i> , 1997, 91, 551-557.	1.6	44
64	Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis. <i>The Lancet Global Health</i> , 2019, 7, e337-e346.	6.3	41
65	Estimating Individual Exposure to Malaria Using Local Prevalence of Malaria Infection in the Field. <i>PLoS ONE</i> , 2012, 7, e32929.	2.5	38
66	Repeated clinical malaria episodes are associated with modification of the immune system in children. <i>BMC Medicine</i> , 2019, 17, 60.	5.5	37
67	The remaining unknowns: a mixed methods study of the current and global health research priorities for COVID-19. <i>BMJ Global Health</i> , 2020, 5, e003306.	4.7	37
68	Malaria protection due to sickle haemoglobin depends on parasite genotype. <i>Nature</i> , 2022, 602, 106-111.	27.8	36
69	Observational study: 27 years of severe malaria surveillance in Kilifi, Kenya. <i>BMC Medicine</i> , 2019, 17, 124.	5.5	33
70	Contrasting signatures of selection on the <i>Plasmodium falciparum</i> erythrocyte binding antigen gene family. <i>Molecular and Biochemical Parasitology</i> , 2006, 149, 182-190.	1.1	32
71	Declining Malaria Transmission Differentially Impacts the Maintenance of Humoral Immunity to <i>Plasmodium falciparum</i> in Children. <i>Journal of Infectious Diseases</i> , 2017, 216, 887-898.	4.0	31
72	<i>Plasmodium falciparum</i> Malaria in Children Aged 0-2 Years: The Role of Foetal Haemoglobin and Maternal Antibodies to Two Asexual Malaria Vaccine Candidates (MSP3 and GLURP). <i>PLoS ONE</i> , 2014, 9, e107965.	2.5	30

#	ARTICLE	IF	CITATIONS
73	Lack of Avidity Maturation of Merozoite Antigen-Specific Antibodies with Increasing Exposure to Plasmodium falciparum amongst Children and Adults Exposed to Endemic Malaria in Kenya. PLoS ONE, 2012, 7, e52939.	2.5	28
74	The use of cryopreserved mature trophozoites in assessing antibody recognition of variant surface antigens of Plasmodium falciparum-infected erythrocytes. Journal of Immunological Methods, 2004, 288, 9-18.	1.4	27
75	Multiple clinical episodes of Plasmodium falciparum malaria in a low transmission intensity setting: exposure versus immunity. BMC Medicine, 2015, 13, 114.	5.5	27
76	A Genome Wide Association Study of Plasmodium falciparum Susceptibility to 22 Antimalarial Drugs in Kenya. PLoS ONE, 2014, 9, e96486.	2.5	27
77	KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization. Frontiers in Immunology, 2018, 9, 2866.	4.8	26
78	Avidity of Anti-Circumsporozoite Antibodies following Vaccination with RTS,S/AS01E in Young Children. PLoS ONE, 2014, 9, e115126.	2.5	26
79	Identifying children with excess malaria episodes after adjusting for variation in exposure: identification from a longitudinal study using statistical count models. BMC Medicine, 2015, 13, 183.	5.5	25
80	A single point in protein trafficking by Plasmodium falciparum determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies. Cellular and Molecular Life Sciences, 2016, 73, 4141-4158.	5.4	20
81	The effect of declining exposure on T cell-mediated immunity to Plasmodium falciparum – an epidemiological “natural experiment”. BMC Medicine, 2016, 14, 143.	5.5	20
82	Cord blood IgG and the risk of severe Plasmodium falciparum malaria in the first year of life. International Journal for Parasitology, 2017, 47, 153-162.	3.1	19
83	Funding and COVID-19 research priorities - are the research needs for Africa being met?. AAS Open Research, 2020, 3, 56.	1.5	18
84	Mapping genetic markers of artemisinin resistance in Plasmodium falciparum malaria in Asia: a systematic review and spatiotemporal analysis. Lancet Microbe, The, 2022, 3, e184-e192.	7.3	16
85	Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity. Vaccine, 2016, 34, 160-166.	3.8	15
86	Doxycycline for the treatment of nodding syndrome (DONS); the study protocol of a phase II randomised controlled trial. BMC Neurology, 2019, 19, 35.	1.8	14
87	Patients’ preferences of cutaneous leishmaniasis treatment outcomes: Findings from an international qualitative study. PLoS Neglected Tropical Diseases, 2020, 14, e0007996.	3.0	14
88	Chloroquine is not a risk factor for seizures in childhood cerebral malaria. Tropical Medicine and International Health, 2000, 5, 860-864.	2.3	13
89	30 years of science and technology: the example of malaria. Lancet, The, 1997, 349, S1-S2.	13.7	12
90	Gene copy number variation in natural populations of Plasmodium falciparum in Eastern Africa. BMC Genomics, 2018, 19, 372.	2.8	12

#	ARTICLE	IF	CITATIONS
91	Use of gene expression studies to investigate the human immunological response to malaria infection. <i>Malaria Journal</i> , 2019, 18, 418.	2.3	11
92	T-Cell Responses to the DBLÎ±-Tag, a Short Semi-Conserved Region of the Plasmodium falciparum Membrane Erythrocyte Protein 1. <i>PLoS ONE</i> , 2012, 7, e30095.	2.5	11
93	Gametocyte carriage in an era of changing malaria epidemiology: A 19-year analysis of a malaria longitudinal cohort. <i>Wellcome Open Research</i> , 2019, 4, 66.	1.8	10
94	Systemic and cerebrospinal fluid immune and complement activation in Ugandan children and adolescents with longâ€standing nodding syndrome: A caseâ€control study. <i>Epilepsia Open</i> , 2021, 6, 297-309.	2.4	10
95	A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01E on blood stage immunity in young Kenyan children. <i>Wellcome Open Research</i> , 2019, 4, 42.	1.8	10
96	Gametocyte carriage in an era of changing malaria epidemiology: A 19-year analysis of a malaria longitudinal cohort. <i>Wellcome Open Research</i> , 2019, 4, 66.	1.8	10
97	Characterization of Naturally Acquired Immunity to a Panel of Antigens Expressed in Mature P. falciparum Gametocytes. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 774537.	3.9	10
98	Signs of Dehydration in Severe Childhood Malaria. <i>Tropical Doctor</i> , 1997, 27, 235-236.	0.5	9
99	Risk Factors for Nodding Syndrome and Other Forms of Epilepsy in Northern Uganda: A Case-Control Study. <i>Pathogens</i> , 2021, 10, 1451.	2.8	9
100	Asymptomatic malaria parasitaemia and seizure control in children with nodding syndrome; a cross-sectional study. <i>BMJ Open</i> , 2018, 8, e023624.	1.9	8
101	Patient-centered benefit-risk analysis of transcatheter aortic valve replacement. <i>F1000Research</i> , 2019, 8, 394.	1.6	8
102	Serological Conservation of Parasite-Infected Erythrocytes Predicts Plasmodium falciparum Erythrocyte Membrane Protein 1 Gene Expression but Not Severity of Childhood Malaria. <i>Infection and Immunity</i> , 2016, 84, 1331-1335.	2.2	7
103	Few Plasmodium falciparum merozoite ligand and erythrocyte receptor pairs show evidence of balancing selection. <i>Infection, Genetics and Evolution</i> , 2019, 69, 235-245.	2.3	7
104	10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity. <i>Wellcome Open Research</i> , 2021, 6, 79.	1.8	7
105	Epilepsy in Onchocerca volvulus Sero-Positive Patients From Northern Ugandaâ€™ Clinical, EEG and Brain Imaging Features. <i>Frontiers in Neurology</i> , 2021, 12, 687281.	2.4	7
106	An international qualitative study exploring patientsâ€™ experiences of cutaneous leishmaniasis: study set-up and protocol. <i>BMJ Open</i> , 2018, 8, e021372.	1.9	6
107	Antigenic cartography of immune responses to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). <i>PLoS Pathogens</i> , 2019, 15, e1007870.	4.7	6
108	Individual-level variations in malaria susceptibility and acquisition of clinical protection. <i>Wellcome Open Research</i> , 2021, 6, 22.	1.8	6

#	ARTICLE	IF	CITATIONS
109	Equity for excellence in academic institutions: a manifesto for change. Wellcome Open Research, 2021, 6, 142.	1.8	6
110	Household poverty, schooling, stigma and quality of life in adolescents with epilepsy in rural Uganda. Epilepsy and Behavior, 2021, 114, 107584.	1.7	4
111	Individual-level variations in malaria susceptibility and acquisition of clinical protection. Wellcome Open Research, 0, 6, 22.	1.8	4
112	10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity. Wellcome Open Research, 0, 6, 79.	1.8	4
113	Sickle Cell Anaemia in East Africa: Preliminary Results from a Cohort Study.. Blood, 2006, 108, 3802-3802.	1.4	3
114	Mortality in rural coastal Kenya measured using the Kilifi Health and Demographic Surveillance System: a 16-year descriptive analysis. Wellcome Open Research, 0, 6, 327.	1.8	3
115	Management of severe malaria: implications for research. British Journal of Clinical Pharmacology, 2003, 55, 460-463.	2.4	2
116	Plasmodium falciparum Merozoite Associated Armadillo Protein (PfMAAP) Is Apically Localized in Free Merozoites and Antibodies Are Associated With Reduced Risk of Malaria. Frontiers in Immunology, 2020, 11, 505.	4.8	2
117	Antibody Responses to Crude Gametocyte Extract Predict Plasmodium falciparum Gametocyte Carriage in Kenya. Frontiers in Immunology, 2020, 11, 609474.	4.8	2
118	Malaria and Nutritional Status in Children Living on the Coast of Kenya. Scandinavian Journal of Immunology, 2004, 59, 615-616.	2.7	1
119	Malaria vaccines.. Archives of Disease in Childhood, 1988, 63, 468-470.	1.9	0
120	Clinical and Laboratory Features of Homozygous Sickle Cell Patients in Tanzania; Malaria, Infections and Cerebral Blood Flow Velocity.. Blood, 2005, 106, 3778-3778.	1.4	0